![Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies: Molecular Therapy - Nucleic Acids Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies: Molecular Therapy - Nucleic Acids](https://www.cell.com/cms/attachment/14a79370-f6b3-475d-9389-dc393e2193de/fx1_lrg.jpg)
Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies: Molecular Therapy - Nucleic Acids
![Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies: Molecular Therapy - Nucleic Acids Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies: Molecular Therapy - Nucleic Acids](https://www.cell.com/cms/attachment/b41b92a7-b40a-488e-a0f1-e14d41431ba2/gr3_lrg.jpg)
Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies: Molecular Therapy - Nucleic Acids
![Sustained therapeutic benefits by transient reduction of TDP-43 using ENA-modified antisense oligonucleotides in ALS/FTD mice: Molecular Therapy - Nucleic Acids Sustained therapeutic benefits by transient reduction of TDP-43 using ENA-modified antisense oligonucleotides in ALS/FTD mice: Molecular Therapy - Nucleic Acids](https://www.cell.com/cms/asset/c934cecc-abba-4173-9484-419a9e8c08bc/fx1.jpg)